Our INDx indication extension platform generates licensing opportunities for you to repurpose drugs and candidates as valuable precision medicines, with companion patient stratification biomarkers to reduce development risks and cost, maximizing returns on your R&D
Get a prioritized list of your evaluated precision repositioning opportunities matched to patient subgroups
Full data packages supporting method of use patent filing for assets in new indications
Patient stratification biomarkers identifying potential responders for the secondary indication
Ongoing evaluation of secondary indication potential for your pipeline and in-licensing assets
We evaluate marketed drugs, current development candidates, and in-licensed assets to identify and validate precision repositioning opportunities, prioritizing those with the highest market potential and quickest route to market.
Our evaluation includes detailed analyses of each asset’s:
Understanding the near-term repositioning opportunities creates additional revenue opportunities by putting drugs on the market quicker and cheaper in secondary indications and by providing complementary diagnostics tools alongside each out-licensing drug program.
Our companion stratification biomarkers accurately match your targets to the subgroups of patients who are likely to show positive treatment response from drugs targeting those mechanisms in new indications - accelerating market approval and increasing value-based returns.
We’ve uncovered the mechanistic architecture and biological drivers of diseases at an unprecedented level of detail across dozens of major disorders.
These proprietary insights are stored in DiseaseBank™ ready to systematically map your assets to clinically relevant patient subgroups who will benefit from drugs targeting those mechanisms in secondary indications.
Find out what happened when one of our biopharma partners used INDx to maximize the value of its patented assets by identifying new commercial opportunities for its approved drugs and candidates
Cell Patterns paper reveals the potential to systematically reposition hundreds of drugs into new indications
High-resolution patient stratification rapidly identified repurposing opportunities to treat subgroups of schizophrenia patients
